Truist Securities Maintains Buy on Elevance Health, Lowers Price Target to $560
Portfolio Pulse from richadhand@benzinga.com
Truist Securities analyst Tobey Sommer maintains a Buy rating on Elevance Health (NYSE:ELV) but lowers the price target from $580 to $560.
June 20, 2023 | 1:24 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Truist Securities maintains a Buy rating on Elevance Health (NYSE:ELV) but lowers the price target from $580 to $560.
The news of Truist Securities maintaining a Buy rating on Elevance Health is positive for the stock. However, the lowering of the price target from $580 to $560 may create some uncertainty among investors. The overall impact on the stock price is expected to be neutral in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100